Q-omics provides the consensus-scored TENT5D profile across patient tissues and cancer cell-line models. TENT5D expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TENT5D is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TENT5D RNA expression shows 12,680 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where TENT5D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TENT5D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TENT5D survival associations across molecular data types. TENT5D RNA expression shows survival associations in the most cancer types (16), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TENT5D RNA expression–survival associations across cancer types. High TENT5D expression shows unfavorable associations in UCEC, LIHC, DLBC, STAD and THCA, but favorable associations in PRAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TENT5D RNA expression.
This table summarizes TENT5D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TENT5D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TENT5D shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in STAD, LUSC and LUAD. The KIRC box plot shows higher TENT5D RNA expression in normal versus tumor tissue (log2 FC = −0.141, t-test p < 0.001).
This table shows molecular features associated with TENT5D in patient tissues and cancer cell lines. In patient samples, TENT5D shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TENT5D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
